Ionis Pharmaceuticals Files 8-K on Shareholder Votes and Exhibits
Ticker: IONS · Form: 8-K · Filed: Jun 10, 2024 · CIK: 874015
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
IONIS filed an 8-K on June 6th covering shareholder votes and financials. Standard corporate update.
AI Summary
Ionis Pharmaceuticals, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The earliest event reported was on June 6, 2024. The company, incorporated in Delaware, is headquartered in Carlsbad, California.
Why It Matters
This filing provides updates on corporate governance matters and financial reporting, which are crucial for investors to understand the company's operational and shareholder engagement status.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- June 6, 2024 (date) — Earliest event reported
- June 10, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Carlsbad, CA (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these exhibits is not detailed in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on June 6, 2024.
What is Ionis Pharmaceuticals' principal executive office address?
Ionis Pharmaceuticals' principal executive office is located at 2855 Gazelle Court, Carlsbad, CA 92010.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-06-10 16:33:55
Filing Documents
- ef20030961_8k.htm (8-K) — 40KB
- 0001140361-24-029588.txt ( ) — 172KB
- ions-20240606.xsd (EX-101.SCH) — 4KB
- ions-20240606_lab.xml (EX-101.LAB) — 21KB
- ions-20240606_pre.xml (EX-101.PRE) — 16KB
- ef20030961_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. Ionis Pharmaceuticals, Inc. (the " Company ") held its virtual Annual Meeting of Stockholders on June 6, 2024. The stockholders considered four proposals, each of which is described in more detail in the Company's definitive proxy statement dated April 25, 2024. Proposal 1: Election of directors to hold office until the 2027 Annual Meeting: FOR AGAINST ABSTAIN BROKER NON-VOTES Brett P. Monia 120,462,201 2,850,850 157,065 10,132,983 Michael Yang 109,136,314 14,191,316 142,486 10,132,983 The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee. Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2024 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission." FOR AGAINST ABSTAIN BROKER NON-VOTES 118,899,475 4,228,901 341,740 10,132,983 The Company's stockholders approved the foregoing proposal. Proposal 3 : Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards: FOR AGAINST ABSTAIN BROKER NON-VOTES 96,453,407 26,912,642 104,067 10,132,983 The Company's stockholders approved the foregoing proposal. Proposal 4: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year: FOR AGAINST ABSTAIN BROKER NON-VOTES 129,900,428 3,455,435 247,236 0 The
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: June 10, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel